sintilimab + chemotherapy + nimotuzumab

This investigational combination regimen consists of the PD-1 inhibitor sintilimab, the anti-EGFR monoclonal antibody nimotuzumab, and a chemotherapy backbone (typically cisplatin and paclitaxel). It is being evaluated as an induction therapy followed by definitive chemoradiotherapy with nimotuzumab and maintenance sintilimab for patients with locally advanced head and neck squamous cell carcinoma (LA-SCCHN). Sintilimab works by blocking the interaction between PD-1 on T cells and its ligands, thereby restoring anti-tumor immune responses. Nimotuzumab targets the epidermal growth factor receptor (EGFR), which is frequently overexpressed in head and neck cancers, inhibiting downstream signaling pathways involved in cell proliferation and survival. The addition of chemotherapy provides direct cytotoxic effects and may enhance the immunogenicity of the tumor, potentially improving outcomes in the locally advanced setting.

Other names

sintilimab plus nimotuzumab and chemotherapysintilimab combined with chemotherapy and nimotuzumab